UCB (ENXTBR:UCB) - Cotización, noticias y análisis

Resumen de acción UCB

UCB SA, empresa biofarmacéutica, desarrolla productos y soluciones para personas con enfermedades neurológicas e inmunológicas en todo el mundo.

Acerca de la empresa

UCB fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	1/6
Financial Health	4/6
Dividends	0/6

Recompensas

Cotiza un 50.8% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 25.22%

Análisis de riesgos

No se han detectado riesgos en UCB a partir de nuestros controles de riesgos.

Competidores de UCB SA

Financière de Tubize

ENXTBR:TUB

€4.3b

Otsuka Holdings

TSE:4578

JP¥3.6t

Royalty Pharma

NasdaqGS:RPRX

US$16.5b

Sandoz Group

SWX:SDZ

CHF13.4b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for UCB
Historical stock prices
Current Share Price	€124.55
52 Week High	€125.25
52 Week Low	€65.40
Beta	0.40
1 Month Change	8.87%
3 Month Change	43.39%
1 Year Change	47.12%
3 Year Change	63.41%
5 Year Change	79.52%
Change since IPO	40,717.86%

Noticias y actualizaciones recientes

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19

Recent updates

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jul 31

Is UCB (EBR:UCB) A Risky Investment?

Jun 21

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

May 13

Is UCB (EBR:UCB) Using Too Much Debt?

Mar 18

Will Weakness in UCB SA's (EBR:UCB) Stock Prove Temporary Given Strong Fundamentals?

Feb 28

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 54% Above Its Share Price

Feb 10

What Makes UCB SA (EBR:UCB) A Great Dividend Stock?

Jan 20

Is UCB SA (EBR:UCB) Popular Amongst Institutions?

Jan 07

UCB (EBR:UCB) Is Growing Earnings But Are They A Good Guide?

Dec 23

Rentabilidad de los accionistas

	UCB	BE Pharmaceuticals	Mercado BE
7D	3.1%	2.5%	-0.3%
1Y	47.1%	9.7%	-2.4%

Rentabilidad vs. Industria: UCB superó al sector Belgian Pharmaceuticals , que obtuvo un rendimiento del 8.7% el año pasado.

Rentabilidad vs. Mercado: UCB superó al mercado Belgian, que obtuvo un rendimiento del -2.8% el año pasado.

Volatilidad de los precios

Is UCB's price volatile compared to industry and market?
UCB volatility
UCB Average Weekly Movement	3.7%
Pharmaceuticals Industry Average Movement	5.0%
Market Average Movement	3.7%
10% most volatile stocks in BE Market	7.6%
10% least volatile stocks in BE Market	2.5%

Precio estable de las acciones: El precio de las acciones de UCB ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de UCB (4%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1925	8,767	Jean-Christophe Tellier	www.ucb.com

UCB SA, empresa biofarmacéutica, desarrolla productos y soluciones para personas con enfermedades neurológicas e inmunológicas en todo el mundo. Los principales productos de la empresa incluyen Cimzia para enfermedades inflamatorias mediadas por TNF, así como espondilitis anquilosante, espondiloartritis axial, enfermedad de Crohn, espondiloartritis axial no radiográfica, psoriasis en placas, artritis psoriásica y artritis reumatoide; Vimpat, Keppra y Briviact para la epilepsia; Neupro para la enfermedad de Parkinson y el síndrome de las piernas inquietas; Nayzilam, un tratamiento de rescate en aerosol nasal para las crisis de epilepsia; y Zyrtec y Xyzal para las alergias. También ofrece Evenity para el tratamiento de la osteoporosis en mujeres posmenopáusicas; Bimzelx para tratar la psoriasis en placas, la artritis psoriásica y la espondiloartritis axial; y Fintepla para tratar el síndrome de Dravet.

Resumen de fundamentos de UCB SA

¿Cómo se comparan los beneficios e ingresos de UCB con su capitalización de mercado?
Estadísticas fundamentales de UCB
Capitalización bursátil	€23.63b
Beneficios(TTM)	€343.00m
Ingresos (TTM)	€5.18b

68.9x

Ratio precio-beneficio (PE)

4.6x

Ratio precio-ventas (PS)

¿Está UCB sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de UCB
Ingresos	€5.18b
Coste de los ingresos	€1.71b
Beneficio bruto	€3.48b
Otros gastos	€3.13b
Beneficios	€343.00m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

Jul 25, 2024

Beneficios por acción (BPA)	1.81
Margen bruto	67.06%
Margen de beneficio neto	6.62%
Ratio deuda/patrimonio	32.1%

¿Cómo se ha desempeñado UCB a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

1.1%

Rentabilidad actual por dividendo

75%

Ratio de pagos

Resumen de acción UCB

Recompensas

Análisis de riesgos

Competidores de UCB SA

ENXTBR:TUB

€4.3b

TSE:4578

JP¥3.6t

NasdaqGS:RPRX

US$16.5b

SWX:SDZ

CHF13.4b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

Dividend of €0.95 announced

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Consensus EPS estimates increase by 18%

Recent updates

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

Dividend of €0.95 announced

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Consensus EPS estimates increase by 18%

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

Is UCB (EBR:UCB) A Risky Investment?

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Price target increased by 9.4% to €111

Consensus EPS estimates fall by 14%

Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB SA's (EBR:UCB) P/E Is On The Mark

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Is UCB (EBR:UCB) Using Too Much Debt?

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Upcoming dividend of €0.93 per share at 1.5% yield

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

First half 2022 earnings released

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB (EBR:UCB) Is Paying Out A Larger Dividend Than Last Year